Should I buy or sell CureVac stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares. View CVAC analyst ratings or view top-rated stocks .

What is CureVac's stock price target for 2024?

3 Wall Street research analysts have issued 12 month target prices for CureVac's stock. Their CVAC share price targets range from $8.00 to $24.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 483.7% from the stock's current price. View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts .

How have CVAC shares performed in 2024?

CureVac's stock was trading at $4.21 at the beginning of 2024. Since then, CVAC shares have decreased by 39.0% and is now trading at $2.57. View the best growth stocks for 2024 here .

When is CureVac's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our CVAC earnings forecast .

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) posted its quarterly earnings data on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($54.37) by $54.13.

What ETFs hold CureVac's stock?

ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) . Morningstar US Small Growth (MSGR) .

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA) , Tesla (TSLA) , Novavax (NVAX) , Inovio Pharmaceuticals (INO) , Gilead Sciences (GILD) , Pfizer (PFE) , Johnson & Johnson (JNJ) , Zoom Video Communications (ZM) and NIO (NIO) .

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Who are CureVac's major shareholders?

CureVac's stock is owned by many different institutional and retail investors. Top institutional shareholders include Ballentine Partners LLC (0.01%).

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CVAC

CureVac (CVAC) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CVAC Stock Alerts

$2.57

-0.10 (-3.75%)

(As of 04/17/2024 ET)

Compare

Today's Range: $2.54
▼
$2.73
50-Day Range: $2.57
▼
$3.58
52-Week Range: $2.54
▼
$12.36

Volume: 921,152 shs
Average Volume: 730,645 shs
Market Capitalization: $575.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get CureVac alerts:

CureVac MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 483.7% Upside
$15.00 Price Target
Short Interest: Bearish
5.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.88
Upright™ Environmental Score
News Sentiment: -0.79
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.97) to ($0.63) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

337th out of 913 stocks

Pharmaceutical Preparations Industry

135th out of 396 stocks

3.0

Analyst's Opinion

Consensus Rating
CureVac has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.
Amount of Analyst Coverage
CureVac has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.47% of the float of CureVac has been sold short.
Short Interest Ratio / Days to Cover
CureVac has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in CureVac has recently increased by 3.09%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
CureVac does not currently pay a dividend.
Dividend Growth
CureVac does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CureVac has received a 80.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for CureVac is -1.88.

1.2

News and Social Media Coverage

News Sentiment
CureVac has a news sentiment score of -0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for CureVac this week, compared to 2 articles on an average week.
MarketBeat Follows
4 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CureVac insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 17.26% of the stock of CureVac is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for CureVac are expected to grow in the coming year, from ($0.97) to ($0.63) per share.
Price to Book Value per Share Ratio
CureVac has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About CureVac Stock (NASDAQ:CVAC)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CVAC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CVAC Stock News Headlines

April 18, 2024 | americanbankingnews.com

CureVac (NASDAQ:CVAC) Hits New 52-Week Low at $2.54

April 17, 2024 | markets.businessinsider.com

EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 16, 2024 | seekingalpha.com

CureVac, MD Anderson team up for cancer vaccines

April 16, 2024 | msn.com

CureVac, MD Anderson teams up for cancer vaccines

April 4, 2024 | msn.com

CureVac, GSK Partner Release Data On Influenza Vaccine Study

April 4, 2024 | markets.businessinsider.com

EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

March 25, 2024 | finance.yahoo.com

CureVac N.V.: CureVac Provides Risk-Tolerant Investors With Pure-Play Exposure to mRNA Candidates

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 16, 2024 | finance.yahoo.com

CVAC Oct 2024 7.500 call

March 8, 2024 | seekingalpha.com

CureVac: No Momentum In Sight

February 1, 2024 | msn.com

Jimmy Kimmel Gives Trump A Brutal Reality Check On Just How Unpopular He Is

February 1, 2024 | finance.yahoo.com

Here's Why We're Watching CureVac's (NASDAQ:CVAC) Cash Burn Situation

January 26, 2024 | finance.yahoo.com

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

January 25, 2024 | finance.yahoo.com

Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

January 6, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), CureVac (CVAC) and Immunocore Holdings (IMCR)

January 5, 2024 | msn.com

Why Biopharmaceutical Player CureVac Shares Are Rising Today

January 5, 2024 | markets.businessinsider.com

CureVac Announces Positive Phase 2 Results For COVID-19 Vaccine Candidates

December 22, 2023 | finance.yahoo.com

These Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS Forecasts

December 20, 2023 | realmoney.thestreet.com

CureVac price target lowered to $6.40 from $8 at BofA

December 20, 2023 | markets.businessinsider.com

CureVac Buy Rating Affirmed Despite Patent Setback, Strong Appeal Prospects Anticipated

December 19, 2023 | bizjournals.com

German patent court deals CureVac a blow to Covid vaccine IP

December 19, 2023 | marketwatch.com

CureVac stock down 43.5% in premarket trading

December 19, 2023 | markets.businessinsider.com

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

December 19, 2023 | finance.yahoo.com

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

December 19, 2023 | msn.com

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

December 18, 2023 | lse.co.uk

Curevac Share Price (1CVAC.MI)

See More Headlines

Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/29/2020
Today: 4/18/2024
Next Earnings (Estimated): 6/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CVAC
CUSIP: N/A
CIK: 1809122
Web: www.curevac.com
Phone: 49-70-71988-30
Fax: 49-7071-9883
Employees: 1,049
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $24.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +483.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 3.56
Quick Ratio: 3.41

Sales & Book Value

Annual Sales: $42.88 million
Price / Sales: 13.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.88 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 223,880,000
Free Float: N/A
Market Cap: $575.37 million
Optionable: Optionable
Beta: 2.51

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Pierre Kemula B.Sc. (Age 49)
MD, CFO & Member of Management Board
Comp: $594.58k
Dr. Malte Greune Ph.D. (Age 59)
COO, Member of Management Board & MD
Comp: $462.41k
Dr. Ulrike Gnad-Vogt M.D. (Age 51)
Ph.D., Senior VP & Area Head of Oncology
Comp: $379.65k
Dr. Alexander Zehnder M.B.A. (Age 54)
M.D., CEO, MD & Member of Management Board
Dr. Myriam Mendila M.D. (Age 58)
Chief Development Officer, MD & Member of the Management Board
Dr. Sarah Fakih
Vice President Corporate Communications & Investor Relations
Mr. Marco Rau L.L.M.
Ph.D., General Counsel
Mr. Thorsten Schuller
Head of Corporate Communications
Slavica Stevanovic-Heck
Head of Human Resources
Dr. Patrick Baumhof
Senior Vice President of Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CVAC Stock Analysis - Frequently Asked Questions

Should I buy or sell CureVac stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares.
View CVAC analyst ratings or view top-rated stocks.
What is CureVac's stock price target for 2024?: 3 Wall Street research analysts have issued 12 month target prices for CureVac's stock. Their CVAC share price targets range from $8.00 to $24.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 483.7% from the stock's current price.
View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts.
How have CVAC shares performed in 2024?: CureVac's stock was trading at $4.21 at the beginning of 2024. Since then, CVAC shares have decreased by 39.0% and is now trading at $2.57.
View the best growth stocks for 2024 here.
When is CureVac's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our CVAC earnings forecast.
How were CureVac's earnings last quarter?: CureVac (NASDAQ:CVAC) posted its quarterly earnings data on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($54.37) by $54.13.
What ETFs hold CureVac's stock?: ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Morningstar US Small Growth (MSGR).

What other stocks do shareholders of CureVac own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).
When did CureVac IPO?: CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.
Who are CureVac's major shareholders?: CureVac's stock is owned by many different institutional and retail investors. Top institutional shareholders include Ballentine Partners LLC (0.01%).
How do I buy shares of CureVac?: Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVAC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CureVac (CVAC) Stock Price, News & Analysis

CureVac MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CureVac Stock (NASDAQ:CVAC)

CVAC Stock Price History

CVAC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CVAC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™